This Frontline Therapy Is Better in Multiple Myeloma: Study This Frontline Therapy Is Better in Multiple Myeloma: Study

A study directly comparing real-world outcomes suggests patients with transplant-ineligible multiple myeloma do better with frontline triple therapy with daratumumab vs bortezomib.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news